Switch theme
Sign up to access all valuation multiples
LBX Pharmacy Chain JSC is a China-based company engages in the sale of medicine and health products. The company is engaged in retailing drugs and other related products, including Chinese and Western medicine, prepared slices of Chinese crude drugs, health equipment, healthy food, and personal care products and life care products. The company is also involved in the wholesale and manufacture of drugs.
2005
n/a
LTM Revenue $3.2B
LTM EBITDA $333M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LBX Pharmacy has a last 12-month revenue (LTM) of $3.2B and a last 12-month EBITDA of $333M.
In the most recent fiscal year, LBX Pharmacy achieved revenue of $3.1B and an EBITDA of $356M.
LBX Pharmacy expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LBX Pharmacy valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2B | XXX | $3.1B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $333M | XXX | $356M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $163M | XXX | $167M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $88.3M | XXX | $72.0M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $93.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, LBX Pharmacy's stock price is CNY 19 (or $3).
LBX Pharmacy has current market cap of CNY 14.6B (or $2.0B), and EV of CNY 17.4B (or $2.4B).
See LBX Pharmacy trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.0B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, LBX Pharmacy has market cap of $2.0B and EV of $2.4B.
LBX Pharmacy's trades at 0.8x EV/Revenue multiple, and 6.8x EV/EBITDA.
Equity research analysts estimate LBX Pharmacy's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LBX Pharmacy has a P/E ratio of 23.0x.
See valuation multiples for LBX Pharmacy and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 7.3x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBIT | 14.8x | XXX | 14.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.0x | XXX | 28.2x | XXX | XXX | XXX |
| EV/FCF | 16.4x | XXX | 11.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLBX Pharmacy's last 12 month revenue growth is 8%
LBX Pharmacy's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
LBX Pharmacy's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LBX Pharmacy's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for LBX Pharmacy and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | -5% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LBX Pharmacy acquired XXX companies to date.
Last acquisition by LBX Pharmacy was XXXXXXXX, XXXXX XXXXX XXXXXX . LBX Pharmacy acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was LBX Pharmacy founded? | LBX Pharmacy was founded in 2005. |
| Where is LBX Pharmacy headquartered? | LBX Pharmacy is headquartered in China. |
| Is LBX Pharmacy publicy listed? | Yes, LBX Pharmacy is a public company listed on SHG. |
| What is the stock symbol of LBX Pharmacy? | LBX Pharmacy trades under 603883 ticker. |
| When did LBX Pharmacy go public? | LBX Pharmacy went public in 2015. |
| Who are competitors of LBX Pharmacy? | Similar companies to LBX Pharmacy include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of LBX Pharmacy? | LBX Pharmacy's current market cap is $2.0B |
| What is the current revenue of LBX Pharmacy? | LBX Pharmacy's last 12 months revenue is $3.2B. |
| What is the current revenue growth of LBX Pharmacy? | LBX Pharmacy revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of LBX Pharmacy? | Current revenue multiple of LBX Pharmacy is 0.8x. |
| Is LBX Pharmacy profitable? | Yes, LBX Pharmacy is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of LBX Pharmacy? | LBX Pharmacy's last 12 months EBITDA is $333M. |
| What is LBX Pharmacy's EBITDA margin? | LBX Pharmacy's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of LBX Pharmacy? | Current EBITDA multiple of LBX Pharmacy is 7.3x. |
| What is the current FCF of LBX Pharmacy? | LBX Pharmacy's last 12 months FCF is $148M. |
| What is LBX Pharmacy's FCF margin? | LBX Pharmacy's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of LBX Pharmacy? | Current FCF multiple of LBX Pharmacy is 16.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
